FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,010 · see citing works

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

Chung, J., Kuo, C. J., Crabtree, G. R., & Blenis, J. (1992) · Cell · doi:10.1016/0092-8674(92)90643-q · Cited by 1,151 · see citing works

Formation and Activation of a Cyclin E-cdk2 Complex During the G 1 Phase of the Human Cell Cycle

Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S. J., Nishimoto, T., Morgan, D. O., Franza, B. R., & Roberts, J. M. (1992) · Science · doi:10.1126/science.1388288 · Cited by 1,043 · see citing works

D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA

Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021 · see citing works

Functional interactions of the retinoblastoma protein with mammalian D-type cyclins

Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010 · see citing works

A family of human cdc2‐related protein kinases.

Meyerson, M. M., Enders, G. H., Wu, C. L., Su, L., Gorka, C., Nelson, C. E., Harlow, E., & Tsai, L. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 925 · see citing works

Identification and properties of an atypical catalytic subunit (p34PSK-J3/Cdk4) for mammalian D type G1 cyclins

Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897 · see citing works

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

Kunz, J., Henríquez, R., Schneider, U., Deuter‐Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 838 · see citing works

Physical interaction of the retinoblastoma protein with human D cyclins

Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., & Weinberg, R. A. (1993) · Cell · doi:10.1016/0092-8674(93)90137-f · Cited by 746 · see citing works

Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.

Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G. R., & Schreiber, S. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9231 · Cited by 695 · see citing works

Rapamycin-Induced Inhibition of the 70-Kilodalton S6 Protein Kinase

Price, D. J., Grove, J. R., Calvo, V., Avruch, J., & Bierer, B. E. (1992) · Science · doi:10.1126/science.1380182 · Cited by 666 · see citing works

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

Kuo, C. J., Chung, J., Fiorentino, D. F., Flanagan, W. M., Blenis, J., & Crabtree, G. R. (1992) · Nature · doi:10.1038/358070a0 · Cited by 594 · see citing works

The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.

Dumont, F. J., Melino, M. R., Staruch, M. J., Koprak, S., Fischer, P. A., & SIGAL, N. H. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.4.1418 · Cited by 355 · see citing works

Probing Immunosuppressant Action with a Nonnatural Immunophilin Ligand

Bierer, B. E., Somers, P. K., Wandless, T. J., Burakoff, S. J., & Schreiber, S. L. (1990) · Science · doi:10.1126/science.1700475 · Cited by 351 · see citing works

Rapamycin Sensitivity in Saccharomyces cerevisiae Is Mediated by a Peptidyl-Prolyl cis-trans Isomerase Related to Human FK506-Binding Protein

Koltin, Y., Faucette, L. F., Bergsma, D. J., Levy, M. A., Cafferkey, R., Koser, P. L., Johnson, R. K., & Livi, G. P. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.3.1718-1723.1991 · Cited by 249 · see citing works

Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes

Ajchenbaum, F., Ando, K., DeCaprio, J. A., & Griffin, J. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53587-0 · Cited by 237 · see citing works

CDK2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle.

Elledge, S. J., Richman, R., Hall, F. L., Williams, R. T., Lodgson, N., & Harper, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2907 · Cited by 224 · see citing works

Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.

Morice, W. G., Brunn, G. J., Wiederrecht, G., Siekierka, J. J., & Abraham, R. T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53755-8 · Cited by 180 · see citing works

Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin.

Calvo, V., Crews, C. M., Vik, T. A., & Bierer, B. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7571 · Cited by 163 · see citing works

Phosphorylation independent activation of human cyclin-dependent kinase 2 by cyclin A in vitro.

Connell‐Crowley, L., Solomon, M. J., Wei, N., & Harper, J. W. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.1.79 · Cited by 158 · see citing works

FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins.

Wiederrecht, G., Brizuela, L., Elliston, K. O., SIGAL, N. H., & Siekierka, J. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.1029 · Cited by 98 · see citing works

Characterization of the cytoplasmic proline-directed protein kinase in proliferative cells and tissues as a heterodimer comprised of p34cdc2 and p58cyclin A.

Hall, F. L., Braun, R., Mihara, K., Fung, Y. K., Berndt, N., Carbonaro-Hall, D. A., & Vulliet, P. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47391-2 · Cited by 63 · see citing works

Effects of Rapamycin on Cultured Hepatocyte Proliferation and Gene Expression

Francavilla, A., Carr, B. I., Starzl, T. E., Azzarone, A., Carrieri, G., & Zeng, Q. H. (1992) · Hepatology · doi:10.1002/hep.1840150520 · Cited by 56 · see citing works

Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein.

Hall, F. L., Williams, R. T., Wu, L., WU, F., Carbonaro-Hall, D. A., Harper, J. W., & Warburton, D. (1993) · PubMed · Cited by 48 · see citing works

G1 expression and multistage dynamics of cyclin A in human osteosarcoma cells.

Carbonaro-Hall, D. A., Williams, R. T., Li-jun, W., Warburton, D., Zeichner‐David, M., MacDougall, M. J., Tolo, & Hall, F. L. (1993) · PubMed · Cited by 30 · see citing works

Identification of a novel cyclin-like protein in human tumor cells.

Williams, R. T., Wu, L., Carbonaro-Hall, D. A., Tolo, V. T., & Hall, F. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52954-9 · Cited by 26 · see citing works

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · see citing works

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803 · see citing works

RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509 · see citing works

mTOR and cancer: insights into a complex relationship

Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · see citing works

A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., & Abraham, R. T. (2000) · PubMed · Cited by 708 · see citing works

Control of p70 S6 kinase by kinase activity of FRAP in vivo

Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705 · see citing works

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 660 · see citing works

IMMUNOPHARMACOLOGY OF RAPAMYCIN

Abraham, R. T., & Wiederrecht, G. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653 · see citing works

Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family.

Jefferies, H. B. J., Reinhard, C., Kozma, S. C., & Thomas, G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4441 · Cited by 623 · see citing works

Natural products in anticancer therapy

Ab, D. R. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00063-7 · Cited by 606 · see citing works

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

West, K. A., Castillo, S. S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 583 · see citing works

Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.

Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556 · see citing works

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

Fibrillar Collagen Inhibits Arterial Smooth Muscle Proliferation through Regulation of Cdk2 Inhibitors

Koyama, H., Raines, E. W., Bornfeldt, K., Roberts, J. M., & Ross, R. (1996) · Cell · doi:10.1016/s0092-8674(00)81801-2 · Cited by 514 · see citing works

mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availabilityPreprint

Mayer, C., Zhao, J., Yuan, X., & Grummt, I. (2004) · Genes & Development · doi:10.1101/gad.285504 · Cited by 506 · see citing works

CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest

Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 495 · see citing works

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.

Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481 · see citing works

Mechanism of action of the immunosuppressant rapamycin

Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 356 · see citing works

Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability

Hashemolhosseini, S., Nagamine, Y., Morley, S., Desrivières, S., Merćep, L., & Ferrari, S. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 343 · see citing works

The TOR pathway comes of age

Stanfel, M. N., Shamieh, L. S., Kaeberlein, M. R., & Kennedy, B. K. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.007 · Cited by 339 · see citing works

Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.

Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., & Houghton, P. J. (1999) · PubMed · Cited by 310 · see citing works

Inhibitors of protein kinases and phosphatases

MacKintosh, C., & MacKintosh, R. W. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90127-9 · Cited by 264 · see citing works

Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells

Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21932 · Cited by 256 · see citing works

Rapamycin: an anti-cancer immunosuppressant?

Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252 · see citing works

Cell Cycle Control

Jacobs, T. W. (1995) · Annual Review of Plant Physiology and Plant Molecular Biology · doi:10.1146/annurev.pp.46.060195.001533 · Cited by 252 · see citing works

Immunophilins in protein folding and immunosuppression 1

Fruman, D. A., Burakoff, S. J., & Bierer, B. E. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.6.7513288 · Cited by 249 · see citing works

Peptidylproline cis/trans isomerases

Gałat, A., & Metcalfe, S. M. (1995) · Progress in Biophysics and Molecular Biology · doi:10.1016/0079-6107(94)00009-x · Cited by 240 · see citing works

The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling

Chou, M. M., & Blenis, J. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80064-6 · Cited by 237 · see citing works

TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin

Lorenz, M. C., & Heitman, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27531 · Cited by 236 · see citing works

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M. G., Arbuck, S. G., Travis, R., Sausville, E. A., & Houghton, P. J. (2001) · PubMed · Cited by 232 · see citing works

Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells.

Yeh, W., Bierer, B. E., & McKnight, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11086 · Cited by 226 · see citing works

Rapamycin Resistance Tied to Defective Regulation of p27 Kip1

Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6744 · Cited by 210 · see citing works

Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1

Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194 · see citing works

Understanding and controlling the cell cycle with natural products

Hung, D. T., Jamison, T. F., & Schreiber, S. L. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90129-5 · Cited by 183 · see citing works

Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1 cells and primary mouse bone marrow stromal cells

Singha, U. K., Jiang, Y., Yu, S., Luo, M., Lu, Y., Zhang, J., & Xiao, G. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21411 · Cited by 180 · see citing works

FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition

Baughman, G., Wiederrecht, G. J., Campbell, N. F., Martin, M. M., & Bourgeois, S. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4395 · Cited by 173 · see citing works

The p70 S6 Kinase Integrates Nutrient and Growth Signals to Control Translational Capacity

Avruch, J., BELHAM, C. M., Weng, Q. P., Hara, K., & Yonezawa, K. (2001) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-56688-2_5 · Cited by 175 · see citing works

The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-associated Protein Kinase Activity and G1 Progression

Vilella-Bach, M., Nuzzi, P., Fang, Y., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4266 · Cited by 154 · see citing works

Defect in Multiple Cell Cycle Checkpoints in Ataxia-Telangiectasia Postirradiation

Beamish, H., Williams, R. T., Chen, P., & Lavin, M. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20486 · Cited by 137 · see citing works

Mechanisms of resistance to rapamycins

Huang, S., & Houghton, P. J. (2001) · Drug Resistance Updates · doi:10.1054/drup.2002.0227 · Cited by 136 · see citing works

The Biological Role of PI3K Pathway in Lung Cancer

Sarris, E., Saif, M. W., & Syrigos, K. (2012) · Pharmaceuticals · doi:10.3390/ph5111236 · Cited by 127 · see citing works

Cell Replication in the Arterial Wall

Koyama, H., Olson, N. E., Dastvan, F., & Reidy, M. A. (1998) · Circulation Research · doi:10.1161/01.res.82.6.713 · Cited by 127 · see citing works

Mammalian anti proliferative signals and their targets

Massagué, J., & Polyák, K. (1995) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(95)90059-4 · Cited by 123 · see citing works

From Beach to Bedside: History of the Development of Sirolimus

Napoli, K. L., & Taylor, P. J. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200110000-00012 · Cited by 118 · see citing works

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

Yellen, P., Saqcena, M., Salloum, D., Feng, J., Preda, A., Xu, L., Rodrik-Outmezguine, V. S., & Foster, D. A. (2011) · Cell Cycle · doi:10.4161/cc.10.22.18124 · Cited by 117 · see citing works

In vivo antitumor effect of the mTOR inhibitor CCI‐779 and gemcitabine in xenograft models of human pancreatic cancer

Ito, D., Fujimoto, K., Mori, T., Kami, K., Koizumi, M., Toyoda, E., Kawaguchi, Y., & Doi, R. (2005) · International Journal of Cancer · doi:10.1002/ijc.21532 · Cited by 117 · see citing works

The Upregulation of p27Kip1 by Rapamycin Results in G1 Arrest in Exponentially Growing T-Cell Lines

Kawamata, S., Sakaida, H., Hori, T., Maeda, M., & Uchiyama, T. (1998) · Blood · doi:10.1182/blood.v91.2.561 · Cited by 117 · see citing works

FKBP12‐rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol‐4 kinase activity.

Cardenas, M. E., & Heitman, J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00277.x · Cited by 116 · see citing works

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

Gridelli, C., Maione, P., & Rossi, A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0171 · Cited by 106 · see citing works

The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells

Cerovac, V., Garcia, J. L. M., Rubinfeld, H., Buchfelder, M., Losa, M., Florio, T., Páez-Pereda, M., Stalla, G. K., & Theodoropoulou, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2951 · Cited by 104 · see citing works

Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells.

Skotzko, M. J., Wu, L., Anderson, W. F., Gordon, E. M., & Hall, F. L. (1995) · PubMed · Cited by 102 · see citing works

Control of Translation by the Target of Rapamycin Proteins

Gingras, A., Raught, B., & Sonenberg, N. (2001) · Progress in molecular and subcellular biology · doi:10.1007/978-3-662-09889-9_6 · Cited by 99 · see citing works

4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin

Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., & Houghton, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110782200 · Cited by 96 · see citing works

Inhibitors of the mammalian target of rapamycin

Dancey, J. E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.3.313 · Cited by 95 · see citing works

Molecular characterization of a FKBP-type immunophilin from higher plants.

Luan, S., Kudla, J., Gruissem, W., & Schreiber, S. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.6964 · Cited by 91 · see citing works

Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase

Lavin, M. F., Khana, K. K., Beamish, H., Spring, K. J., Watters, D. J., & Shiloh, Y. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89083-0 · Cited by 84 · see citing works

The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase Activity

Sabatini, D. M., Pierchala, B. A., Barrow, R. K., Schell, M. J., & Snyder, S. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.20875 · Cited by 82 · see citing works

Rapamycin specifically interferes with the developmental response of fission yeast to starvation

Weisman, R., Choder, M., & Koltin, Y. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.20.6325-6334.1997 · Cited by 75 · see citing works

The Immunosuppressant Rapamycin Represses Human Immunodeficiency Virus Type 1 Replication

Roy, J., Paquette, J., Fortin, J., & Tremblay, M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3447-3455.2002 · Cited by 79 · see citing works

Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs

Kuhn, D. J. (2004) · Frontiers in bioscience · doi:10.2741/1420 · Cited by 74 · see citing works

G1 phase arrest by the phosphatidylinositol 3‐kinase inhibitor LY 294002 is correlated to up‐regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells

Casagrande, F., Bacqueville, D., Pillaire, M., Malecaze, F., Manenti, S., Breton, M., & Darbon, J.-M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00043-x · Cited by 74 · see citing works

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells

Fruman, D. A., Wood, M. A., Gjertson, C. K., Katz, H. R., Burakoff, S. J., & Bierer, B. E. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250239 · Cited by 72 · see citing works

Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes

Law, M. E., Forrester, E., Chytil, A. M., Corsino, P. E., Green, G., Davis, B. J., Rowe, T. C., & Law, B. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1672 · Cited by 66 · see citing works

Signaling by the transforming growth factor-β receptor

Yingling, J. M., Wang, X., & Bassing, C. H. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00007-2 · Cited by 65 · see citing works

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Hu, Y., Gao, J., Wang, M., & Li, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310649 · Cited by 64 · see citing works

Rapamycin, proliferation and geroconversion to senescence

Blagosklonny, M. V. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1554781 · Cited by 61 · see citing works

Downregulation of Cyclin G1 Expression by Retrovirus-Mediated Antisense Gene Transfer Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation

Zhu, N. L., Wu, L., Liu, P. X., Gordon, E. M., Anderson, W. F., Starnes, V. A., & Hall, F. L. (1997) · Circulation · doi:10.1161/01.cir.96.2.628 · Cited by 61 · see citing works

Phosphatidylinositol 3-kinase related kinases

Abraham, R. T. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80132-4 · Cited by 58 · see citing works

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma

Schuetze, S. M., Zhao, L., Chugh, R. K., Thomas, D. G., Lucas, D. R., Metko, G., Zalupski, M. M., & Baker, L. H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.022 · Cited by 52 · see citing works

Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells

Mu, X., Isaac, C. E., Schott, T., Huard, J., & Weiss, K. R. (2013) · Sarcoma · doi:10.1155/2013/480713 · Cited by 50 · see citing works

Cdc42 Promotes G1 Progression through p70 S6 Kinase-mediated Induction of Cyclin E Expression

Chou, M. M., Robens, J., & Gupta, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305246200 · Cited by 51 · see citing works

Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells

Odaka, Y., Xu, B., Luo, Y., Shen, T., Shang, C., Wu, Y., Zhou, H., & Huang, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt277 · Cited by 50 · see citing works

The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo

Quesniaux, V. F. J., Wehrli, S., Steiner, C. W., Joergensen, J., Schuurman, H., Herrman, P., Schreier, M., & Schüler, W. (1994) · Blood · doi:10.1182/blood.v84.5.1543.1543 · Cited by 50 · see citing works

Translation initiation: a critical signalling node in cancer

Robert, F., & Pelletier, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903241625 · Cited by 48 · see citing works

Rapamycin Selectively Blocks Interleukin-2-induced Proliferating Cell Nuclear Antigen Gene Expression in T Lymphocyte

Feuerstein, N., Huang, D., & Prystowsky, M. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.16.9454 · Cited by 47 · see citing works

Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy

Zhao, M. Y., Auerbach, A., D'Costa, A. M., Rapoport, A. P., Burger, A. M., Sausville, E. A., Stass, S. A., Jiang, F., Sands, A. M., Aguilera, N. S. I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1543 · Cited by 45 · see citing works

LY303511 (2-Piperazinyl-8-phenyl-4 H-1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms

Kristof, A. S., Pacheco–Rodriguez, G., Schremmer, B., & Moss, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.083550 · Cited by 45 · see citing works

Evidence for Cyclin D3 as a Novel Target of Rapamycin in Human T Lymphocytes

Hleb, M., Murphy, S., Wagner, E. F., Hanna, N. N., Sharma, N., Park, J., Li, X. C., Strom, T. B., Padbury, J. F., Tseng, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400638200 · Cited by 45 · see citing works

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib

Dhakal, A., Thomas, R. A., Levine, E. G., Brufsky, A., Takabe, K., Hanna, M. G., Attwood, K. M., Miller, A., Khoury, T., Early, A., et al. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420944864 · Cited by 42 · see citing works

Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.Preprint

Alarcón, C. M., Cardenas, M. E., & Heitman, J. (1996) · Genes & Development · doi:10.1101/gad.10.3.279 · Cited by 42 · see citing works

Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells

García-Morales, P., Hernando, E., Carrasco‐García, E., Menéndez-Gutierrez, M. P., Saceda, M., & Martínez-Lacaci, I. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0363 · Cited by 38 · see citing works

Rapamycin Destabilizes Interleukin-3 mRNA in Autocrine Tumor Cells by a Mechanism Requiring an Intact 3′ Untranslated Region

Banholzer, R., Nair, A. P. K., Hirsch, H. H., Ming, X., & Moroni, C. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3254 · Cited by 35 · see citing works

Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors

Yamamoto-Yamaguchi, Y., Okabe‐Kado, J., Kasukabe, T., & Honma, Y. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00626-9 · Cited by 34 · see citing works

p70 S6 Kinase Activation Is Not Required for Insulin-Like Growth Factor-Induced Differentiation of Rat, Mouse, or Human Skeletal Muscle Cells**This work was supported by research grants from the Direccion General de Investigacion Cientifica y Tecnica (PB95/0971), Fondo de Investigacion Sanitaria (97/2101 and 96/0863), and Generalitat de Catalunya (GRQ 94–1040 and 1995 SGR 537), Spain; a postdoctoral fellowship from Comissionat per a Universitats i Recerca, Generalitat de Catalunya (to P.K.); and a predoctoral fellowship from the Ministerio de Educacion y Cultura (to J.C.).

Canicio, J., Gallardo, E., Illa, I., Testar, X., Palacín, M., Zorzano, A., & Kaliman, P. (1998) · Endocrinology · doi:10.1210/endo.139.12.6360 · Cited by 35 · see citing works

Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment

Dhakal, A., Matthews, C. M., Levine, E. G., Salerno, K. E., Zhang, F., Takabe, K., Early, A., Edge, S. B., O'Connor, T., Khoury, T., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.015 · Cited by 33 · see citing works

Rescue of Degradation‐Prone Mutants of the FK506‐Rapamycin Binding (FRB) Protein with Chemical Ligands

Stankunas, K., Bayle, J. H., Havranek, J. J., Wandless, T. J., Baker, D. A., Crabtree, G. R., & Gestwicki, J. E. (2007) · ChemBioChem · doi:10.1002/cbic.200700087 · Cited by 33 · see citing works

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Cejka, D., Preusser, M., Fuereder, T., Sieghart, W., Werzowa, J. M., Strommer, S., & Wacheck, V. (2008) · PubMed · Cited by 30 · see citing works

Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells

Yue, W., Wang, J., Li, Y., Fan, P., & Santen, R. J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21222 · Cited by 31 · see citing works

Rapamycin inhibits didemnin B‐induced apoptosis in human HL‐60 cells: Evidence for the possible involvement of FK506‐binding protein 25

Johnson, K. L., & Lawen, A. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00821.x · Cited by 30 · see citing works

Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin

Richter, A., Davies, D. E., & Alexander, P. M. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00423-j · Cited by 30 · see citing works

Negative Growth Regulation of SK-N-MC Cells by bFGF Defines a Growth Factor-sensitive Point in G2

Smits, V. A. J., van Peer, M. A., Essers, M. A. G., Klompmaker, R., Rijksen, G., & Medema, R. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001764200 · Cited by 29 · see citing works

Preclinical results of sirolimus treatment in transplant models

Stepkowski, S. M. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00222-7 · Cited by 28 · see citing works

Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells

Pang, H., & Faber, L. E. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1012570204923 · Cited by 26 · see citing works

A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer

Mekonnen, L. B., Tadesse, S., Lenjisa, J. L., Yu, M., Noll, B. D., Heinemann, G. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Beck, A. R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.012 · Cited by 25 · see citing works

Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation

Formica, R. N., Lorber, K. M., Friedman, A. L., BIA, M. J., Lakkis, F. G., Smith, J. D., & Lorber, M. I. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00216-1 · Cited by 23 · see citing works

Immunosuppressive Drugs in HIV Disease

Argyropoulos, C., & Mouzaki, Α. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778194271 · Cited by 23 · see citing works

Rapamycin: Biological and therapeutic effects, binding by immunophilins and molecular targets of action

Wood, M. A., & Bierer, B. E. (1994) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171742 · Cited by 21 · see citing works

Role of NF-kappaB in the control of apoptotic and proliferative responses in IL-2-responsive T cells

Martínez‐A, C. (1997) · Frontiers in bioscience · doi:10.2741/a174 · Cited by 20 · see citing works

Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth

Iwabuchi, T. (1995) · Journal of Dermatological Science · doi:10.1016/0923-1811(94)00351-e · Cited by 20 · see citing works

Rapamycin causes activation of protein phosphatase-2A1 and nuclear translocation of PCNA in CD4+ T cells

Morrow, P. W., Tung, H. Y. L., & Hemmings, H. C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.147 · Cited by 19 · see citing works

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · see citing works

Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line.

Jayaraman, T., & Marks, A. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74403-2 · Cited by 101 · see citing works

The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-associated Protein Kinase Activity and G1 Progression

Vilella-Bach, M., Nuzzi, P., Fang, Y., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4266 · Cited by 154 · see citing works

An FKBP‐Rapamycin‐Sensitive, Cyclin‐Dependent Kinase Activity that Correlates with the FKBP‐Rapamycin‐Induced G1 Arrest Point in MG‐63 Cellsa

Albers, M. W., Brown, E. J., Tanaka, A., Williams, R. T., Hall, F. L., & Schreiber, S. L. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb17142.x · Cited by 16 · see citing works

Rapamycin inhibits cdk4 activation, p 21WAF1/CIP1 expression and G1‐phase progression in transformed mouse fibroblasts

Gaben, A., Saucier, C., Bedin, M., Barbu, V. D., & Mešter, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11521 · Cited by 35 · see citing works